ethamolin and Esophageal-Neoplasms

Topics: Carcinoma, Adenosquamous; Esophageal and Gastric Varices; Esophageal Neoplasms; Hemostasis, Endoscopic; Humans; Male; Middle Aged; Oleic Acids; Sclerosing Solutions; Sclerotherapy

We report two cases of squamous cell carcinoma of the esophagus following endoscopic injection sclerotherapy for esophageal varices. The interval between sclerotherapy and the development of carcinoma was 24 months in case 1 and 21 months in case 2. The sclerosant was 5% sodium morrhuate in case 1 (total dose, 10 ml) and 5% ethanolamine oleate in case 2 (45.5 ml). Although no recurrent variceal bleeding occurred after sclerotherapy, we could not perform any curative surgical treatment for esophageal cancer because of the advanced stage of the cancer and the severity of the accompanying liver dysfunction. It is difficult to determine the relationship between sclerotherapy and carcinoma; however, long-term surveillance is essential to avoid overlooking a neoplasm in the esophagus after endoscopic injection sclerotherapy.

Topics: Carcinoma, Squamous Cell; Esophageal and Gastric Varices; Esophageal Neoplasms; Esophagoscopy; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Oleic Acids; Sclerosing Solutions; Sclerotherapy; Sodium Morrhuate; Time Factors

Topics: Esophageal Neoplasms; Esophagoscopy; Female; Follow-Up Studies; Hemangioma; Humans; Middle Aged; Oleic Acids; Sclerosing Solutions; Sclerotherapy; Treatment Outcome

In the last decade, several cases of patients with esophageal varices treated with endoscopic sclerotherapy who posteriorly developed carcinoma of the gastroesophageal junction have been reported in the literature. This may only be a coincidence, although the existence of an undemonstrated relationship direct cannot be discarded. The case of a patient diagnosed with alcoholic liver cirrhosis with portal hypertension and esophageal varices who underwent several sessions of endoscopic sclerotherapy with ethanolamine oleate is presented. During follow-up dysphagia was observed due to adenocarcinoma of the lower third of the esophagus. Carcinoma of the esophagus should be taken into account as a rare diagnostic possibility in a patient with dysphagia of recent appearance with a history of esophageal varix sclerotherapy.

Topics: Adenocarcinoma; Aged; Biopsy; Esophageal and Gastric Varices; Esophageal Neoplasms; Esophageal Stenosis; Esophagogastric Junction; Esophagus; Humans; Male; Oleic Acids; Prosthesis Implantation; Sclerosing Solutions; Sclerotherapy; Time Factors

We report here three cases of squamous-cell carcinoma of the esophagus following endoscopic injection sclerotherapy for esophageal varices. All three patients were men and cigarette smokers, with a mean age of 58.3 +/- 5.0 years. Hepatitis B and C virus infection tests were negative, and alcoholic cirrhosis was present in each patient. The interval between sclerotherapy and the development of carcinoma was 9, 10, and 33 months, in the respective cases. The sclerosant used was 5% ethanolamine oleate with a mean total volume of 51.0 +/- 18.9 ml. While we have no evidence of a direct relationship between sclerotherapy and esophageal cancer, in patients with alcoholic cirrhosis who have risk factors for esophageal cancer there may be an acceleration of the potential malignancy, as a result of the chronic inflammation related to sclerotherapy. Such patients should be closely followed, using endoscopy.

Topics: Carcinoma, Squamous Cell; Cocarcinogenesis; Esophageal and Gastric Varices; Esophageal Neoplasms; Esophagus; Humans; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Oleic Acids; Sclerosing Solutions; Sclerotherapy; Smoking